DanCann Pharma A/S submits new Application to the Danish Medicine Agency for authorisation to produce cannabis intermediate products

COPENHAGEN, December 17, 2020 – DanCann Pharma A/S (“DanCann Pharma”) (SS: DANCAN), a Danish pharmaceutical biotechnology company powered by cannabinoids, today announced that it has submitted a new Application to the Danish Medicine Agency (DMA) for approval for authorisation to produce cannabis intermediate products.

On 1 January 2018, the four-year medicinal cannabis pilot programme was introduced. As a result, the Danish Medicines Agency is granting authorisations to produce cannabis intermediate products in accordance with section 9(1) of the Act on a Medicinal Cannabis Pilot Programme.

Import, production and export of cannabis primary products and production of cannabis intermediate products are all activities appearing on the authorisation to produce cannabis intermediate products.

Comment by the CCO

The Chief Commercial Officer at DanCann Pharma, John Morell Frellsen, said: “It is a significant step in our efforts to bring a variety of medical cannabis products on the market in Denmark. Today, it is difficult for both doctors and patients to get access to medical cannabis in various forms and for the same reason we are here to change that”, commented John Morell Frellsen.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed cultivation and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com